Comparison of efficacy and safety among axitinib,sunitinib,and sorafenib as neoadjuvant therapy for renal cell carcinoma:a retrospective study  

作　　者：Wen Cai Biao Cai Juan Zhou Yonghui Chen Jin Zhang Yiran Huang Wei Xue Jiwei Huang 

机构地区：[1]Department of Urology,Renji Hospital,School of Medicine,Shanghai Jiao Tong University,160 Pujian Rd.,Pudong District,Shanghai 200127,P.R.China [2]Bio-X Institutes,Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders(Ministry of Education),Shanghai Jiao Tong University,Shanghai 200030,P.R.China

出　　处：《Cancer Communications》2019年第1期510-513,共4页癌症通讯（英文）

基　　金：This study was supported by the research project of Shanghai Science and Technology Commission(18ZR1423200);the Incubating Program for Clinical Research and Innovation of Renji Hospital(PYXJS16-008);the Shen Kang 3-year action plan program(16CR3062B)

摘　　要：Dear editor,Renal cancer accounts for approximately 2%of all can-cer deaths worldwide,and renal cell carcinoma(RCC)is the predominant subtype[1].Radiotherapy and chemo-therapy have been found to have limited roles in the treatment of RCC.However,the treatment outcomes of metastatic RCC(mRCC)have been improved drastically since the application of molecular targeted therapeutic agents such as tyrosine kinase inhibitors(TKIs).TKIs have been gradually used for the preoperative treatment of RCC.

关 键 词：RENAL THERAPY treatment 

分 类 号：R73[医药卫生—肿瘤]